MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in the ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

The company markets two versions of Tyvaso — Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. Both versions are approved for PAH and pulmonary hypertension associated with interstitial ...

The specifics of the company's business force it to constantly be in litigation, for example, with Liquidia, which may lead to the loss of Tyvaso DPI exclusivity in 2025. If generics enter the ...

The rise in royalties was primarily due to higher patient demand for Tyvaso DPI. Collaborations and services revenue grew due to increased manufacturing of Tyvaso DPI for United Therapeutics ...